Latest Net Tangible Assets News

Bailador Technology Investments has increased the valuations of PropHero and MOSH, driving a 4.3 cent pre-tax NTA per share uplift, while fully writing down its investment in Nosto following weaker trading.

Ryder Capital Limited has launched a fresh on-market buy-back program targeting up to 8 million ordinary shares, extending its capital management strategy through mid-2027 without requiring shareholder approval.

Australian Agricultural Company (ASX:AAC) defied North Queensland floods to deliver a 23% jump in operating profit, driven by strong beef pricing and herd valuation gains.

Region Group's investment property portfolio valuation rose by $94.8 million to $4.6 billion as at June 2026, supported by acquisitions and capital expenditure. The group also declared a final FY26 distribution of 7.2 cents per security, suspending its distribution reinvestment plan.

Garda Property Group's industrial portfolio valuation rose by $8.25 million for FY26, driven by Brisbane rent growth and land value increases, pushing the portfolio to $340.56 million.

Freedom Bidco, Inc. has launched a non-binding cash proposal to acquire all Strata shares at A$0.16 each, matching the last traded price before suspension and offering shareholders a rare liquidity event ahead of Strata's expected ASX delisting.

Charter Hall Long WALE REIT (ASX:CLW) has completed a $2 billion secured debt refinancing, extending its debt maturity profile by 1.6 years and reducing credit margins by 20 basis points, while reaffirming FY26 earnings and distribution guidance.

WAM Income Maximiser has raised its fully franked monthly dividends for Q3 2026, riding on an investment portfolio that has outperformed benchmarks by 8% annually since inception with notably lower volatility.

NAOS EX-50 Opportunities Company Limited has initiated an on-market buy-back program targeting up to 4.58 million shares, representing 10% of its issued capital, to run from June 2026 through to June 2027.

MFF Capital Investments’ May update shows a modest fall in net tangible assets per share and outlines a cautious yet optimistic portfolio stance amid geopolitical tensions and technological advances.

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.